CA2103666C - Products containing verapamil and trandolapril - Google Patents
Products containing verapamil and trandolapril Download PDFInfo
- Publication number
- CA2103666C CA2103666C CA002103666A CA2103666A CA2103666C CA 2103666 C CA2103666 C CA 2103666C CA 002103666 A CA002103666 A CA 002103666A CA 2103666 A CA2103666 A CA 2103666A CA 2103666 C CA2103666 C CA 2103666C
- Authority
- CA
- Canada
- Prior art keywords
- trandolapril
- verapamil
- physiologically tolerated
- tolerated salt
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 title claims abstract description 21
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 title claims abstract description 19
- 229960002051 trandolapril Drugs 0.000 title claims abstract description 19
- 229960001722 verapamil Drugs 0.000 title claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims description 15
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 206010003119 arrhythmia Diseases 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 101100172871 Arabidopsis thaliana EXA1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000009989 Posterior Leukoencephalopathy Syndrome Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- -1 flow regulators Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000002932 second-degree atrioventricular block Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4109134.5 | 1991-03-20 | ||
| DE4109134A DE4109134A1 (de) | 1991-03-20 | 1991-03-20 | Erzeugnisse, enthaltend verapamil und trandolapril |
| PCT/EP1992/000511 WO1992016229A1 (de) | 1991-03-20 | 1992-03-07 | Erzeugnisse, enthaltend verapamil und trandolapril |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2103666A1 CA2103666A1 (en) | 1992-09-21 |
| CA2103666C true CA2103666C (en) | 2002-06-11 |
Family
ID=6427795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002103666A Expired - Lifetime CA2103666C (en) | 1991-03-20 | 1992-03-07 | Products containing verapamil and trandolapril |
Country Status (17)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW197945B (enrdf_load_stackoverflow) * | 1990-11-27 | 1993-01-11 | Hoechst Ag | |
| DE4308504A1 (de) * | 1993-03-18 | 1994-09-22 | Knoll Ag | Neue Verwendung einer Kombination aus Verapamil und Trandolapril |
| TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
| RU2543637C2 (ru) * | 2012-12-06 | 2015-03-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здавоохранения Российской Федерации | Пролонгированная фармацевтическая композиция гипотензивного действия и способ ее изготовления |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ202903A (en) * | 1981-12-29 | 1988-01-08 | Hoechst Ag | 1-- pe pyrrol-2-yl-carboxylic acid derivatives and pharmaceutical compositions |
| DE3633496A1 (de) * | 1986-10-02 | 1988-04-14 | Hoechst Ag | Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln |
| CA1323833C (en) * | 1987-04-28 | 1993-11-02 | Yatindra M. Joshi | Pharmaceutical compositions in the form of beadlets and method |
-
1991
- 1991-03-20 DE DE4109134A patent/DE4109134A1/de not_active Withdrawn
-
1992
- 1992-03-07 JP JP50550292A patent/JP3454430B2/ja not_active Expired - Lifetime
- 1992-03-07 DE DE59200776T patent/DE59200776D1/de not_active Expired - Lifetime
- 1992-03-07 AT AT92905718T patent/ATE113844T1/de active
- 1992-03-07 BR BR9205712A patent/BR9205712A/pt not_active Application Discontinuation
- 1992-03-07 ES ES92905718T patent/ES2063581T3/es not_active Expired - Lifetime
- 1992-03-07 WO PCT/EP1992/000511 patent/WO1992016229A1/de active IP Right Grant
- 1992-03-07 CZ CS931450A patent/CZ281286B6/cs not_active IP Right Cessation
- 1992-03-07 AU AU13517/92A patent/AU655242B2/en not_active Expired
- 1992-03-07 CA CA002103666A patent/CA2103666C/en not_active Expired - Lifetime
- 1992-03-07 KR KR1019930702800A patent/KR100211914B1/ko not_active Expired - Lifetime
- 1992-03-07 HU HU9302650A patent/HU212941B/hu unknown
- 1992-03-07 DK DK92905718.0T patent/DK0576452T3/da active
- 1992-03-07 EP EP92200728A patent/EP0508511B1/de not_active Expired - Lifetime
- 1992-03-07 EP EP92905718A patent/EP0576452B1/de not_active Expired - Lifetime
- 1992-03-18 MX MX9201191A patent/MX9201191A/es unknown
- 1992-03-19 ZA ZA922002A patent/ZA922002B/xx unknown
- 1992-03-21 TW TW081102153A patent/TW257673B/zh active
-
1993
- 1993-09-17 NO NO933332A patent/NO306601B1/no not_active IP Right Cessation
-
1995
- 1995-06-30 HU HU95P/P00715P patent/HU211747A9/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU211747A9 (en) | 1995-12-28 |
| ATE113844T1 (de) | 1994-11-15 |
| DK0576452T3 (da) | 1995-04-24 |
| DE59200776D1 (de) | 1994-12-15 |
| AU1351792A (en) | 1992-10-21 |
| ZA922002B (en) | 1993-09-20 |
| EP0508511A1 (de) | 1992-10-14 |
| EP0576452B1 (de) | 1994-11-09 |
| NO933332D0 (no) | 1993-09-17 |
| JP3454430B2 (ja) | 2003-10-06 |
| CZ145093A3 (en) | 1994-02-16 |
| HU212941B (en) | 1996-12-30 |
| BR9205712A (pt) | 1994-06-07 |
| AU655242B2 (en) | 1994-12-08 |
| NO933332L (no) | 1993-09-17 |
| HUT65869A (en) | 1994-07-28 |
| CZ281286B6 (cs) | 1996-08-14 |
| JPH06505720A (ja) | 1994-06-30 |
| DE4109134A1 (de) | 1992-09-24 |
| TW257673B (enrdf_load_stackoverflow) | 1995-09-21 |
| HU9302650D0 (en) | 1993-12-28 |
| EP0576452A1 (de) | 1994-01-05 |
| NO306601B1 (no) | 1999-11-29 |
| MX9201191A (es) | 1993-09-01 |
| EP0508511B1 (de) | 1997-12-10 |
| ES2063581T3 (es) | 1995-01-01 |
| CA2103666A1 (en) | 1992-09-21 |
| WO1992016229A1 (de) | 1992-10-01 |
| KR100211914B1 (ko) | 1999-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0726766B1 (en) | Novel pharmaceutical composition containing the ace inhibitor ramipril and a dihydropyridine compound | |
| SK284923B6 (sk) | Zmes liečiv s antidepresívnym účinkom obsahujúca 2-amino-4,5,6,7- tetrahydro-6-propylaminobenzotiazol a sertralín a jej použitie | |
| KR20020075801A (ko) | 울혈성 심부전 치료의 부분적 지방산 산화 방지제 | |
| KR20010093845A (ko) | 피브레이트와 세리바스타틴의 복합제제 | |
| EP1365761A1 (en) | Therapeutic combination of amlodipine and benazepril | |
| JP2003206238A (ja) | 医薬組成物 | |
| KR102479497B1 (ko) | 바레니클린 서방성 제제 및 이의 제조 방법 | |
| CA1157379A (en) | Method of preparation of pharmaceutical composition for treating peripheral orthostatic hypotention | |
| RU2003100507A (ru) | Фармацевтические композиции | |
| CA2072533A1 (en) | Process for the preparation of a pharmaceutical formulation containing at least two different active substances and use of such a formulation | |
| US5990175A (en) | Prevention of migraine | |
| US5886012A (en) | Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers | |
| CA2103666C (en) | Products containing verapamil and trandolapril | |
| KR100709528B1 (ko) | 혈당콘트롤용 의약조성물 | |
| KR102022694B1 (ko) | 약학 조성물 | |
| US3932652A (en) | Antidepressant compositions | |
| KR100709531B1 (ko) | 당뇨병성 합병증의 예방 또는 진전저지용 의약조성물 | |
| EP1124547A1 (en) | Pharmaceutical combination of mildronate and enalapril | |
| KR970006083B1 (ko) | 위장질환 치료용 의약 조성물 | |
| EP0336950A1 (en) | Potentiation of antihypertensive effect of ace inhibitors | |
| US5182285A (en) | Cell-protective composition for preventing or treating of peptic ulcer | |
| US4716177A (en) | Tolrestat for inhibition of weight gain | |
| KR960008229B1 (ko) | 캡토프릴 서방성 정제 및 그의 제조방법 | |
| US4701467A (en) | Tolrestat as anti-hypertensive agent | |
| JP2621382B2 (ja) | 尿酸排泄剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |